Results 51 to 60 of about 682 (125)

Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open‐Label, Fixed Sequence, Phase 1 Study

Clinical and Translational Science, Volume 19, Issue 4, April 2026.
ABSTRACT Molnupiravir is an orally administered prodrug of β‐D‐N4‐hydroxycytidine (NHC) that is conditionally approved in China for the treatment of mild to moderate COVID‐19 in nonhospitalized adults at high risk of disease progression. Molnupiravir is rapidly absorbed and hydrolyzed to deliver NHC into systemic circulation.
Jixiang Zhu, Danning Zhang, Zhiping Liu, Bei Yan, Yanqiao Zang, Weiwei Zhao, Fang Sun, Brian M. Maas, Mickie H. Cheng, S. Aubrey Stoch, Haiyan Li   +10 more
wiley   +1 more source

Are Tetrapleura tetraptera Phytochemicals Druggable Against SARS‐CoV‐2 Papain‐Like Protein? A Computational Approach

New Zealand Journal of Botany, Volume 64, Issue 1, March 2026.
SARS‐CoV2 Omicron and its substrains are still a critical global health issue and extremely contagious, even with widespread vaccination efforts. Hospitalizations and mortality rates linked to these variants are still prevalent. Current therapeutic options face challenges, including low effectiveness, suboptimal pharmacokinetics, and drug resistance ...
Frank Eric Tatsing Foka, Hazel Tumelo Mufhandu   +1 more
wiley   +1 more source

Disruption of Spike Priming in Virus Entry: Tetrandrine as a Pan‐Coronavirus Inhibitor

MedComm, Volume 6, Issue 9, September 2025.
Tetrandrine inhibits the infection of HCoV‐OC43, HCoV‐229E, SARS‐CoV‐2, and its major variants by blocking virus entry. Specifically, tetrandrine breaks the interaction between TMPRSS2 and Spike, therefore suppress its priming and the following membrane fusion, and induces Spike to degradation.
Kun Wang, Huiqiang Wang, Shuo Wu, Ge Yang, Haiyan Yan, Lijun Qiao, Xingqiong Li, Mengyuan Wu, Jiandong Jiang, Yuhuan Li   +9 more
wiley   +1 more source

Clinical Characteristics and Treatment Efficacy in Patients With SARS‐CoV‐2 Positivity After Nirmatrelvir‐Ritonavir Therapy

Journal of Medical Virology, Volume 97, Issue 5, May 2025.
ABSTRACT Nirmatrelvir‐ritonavir (NMV‐r) has been widely used to treat coronavirus disease 2019 (COVID‐19) for a standard period of 5‐days. However, there are increasing reports of patients with persistent severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) positivity after the standard 5‐day course of NMV‐r treatment.
Huqin Yang, Leyi Gao, Yi Xue, Zhijin Zhang, Lujia Guan, Haifan Zhang, Haomiao Ma, Xuyan Li, Jieqiong Li, Zhaohui Tong   +9 more
wiley   +1 more source

Clinical Characteristics of SARS‐COV‐2 Omicron Variant in Acute Myeloid Leukemia and Acute Lymphocytic Leukemia Patients: A Multi‐Center Retrospective Study

Cancer Reports, Volume 8, Issue 4, April 2025.
ABSTRACT Background The death rate of hematological malignancies is high, and the death rate of patients with COVID‐19 infection is further increased. Although there have been expert consensus and relevant guidelines to introduce the recommendations of the guidelines for patients with hematological malignancies complicated with COVID‐19 infection ...
Lin Wang, Ruihua Mi, Lin Chen, Jia Liu, Haiping Yang, Meng Hu, Zhao Xiaoqiang, Yan Zhang, Xiaobing Xu, Bing Liu, Hongmian Zhao, Li Qianyu, Tao Liu, Chen Zhenzhu, Jinxiao Yao, Ying Yang, Xudong Wei   +16 more
wiley   +1 more source

Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study

Infection and Drug Resistance, 2023
Xiang Zhao,1 Yuan Cheng,1 Meng Zhang,1 Bianba Qianda,2 Baima Zhouma,3 Bianba Yangzhen,3 Yao Zheng,4 Shuo Zhang,5 Huiying Zhao6 1Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, People’s Republic of China ...
Zhao X, Cheng Y, Zhang M, Qianda B, Zhouma B, Yangzhen B, Zheng Y, Zhang S, Zhao H   +8 more
doaj  

Effectiveness and Safety of Simnotrelvir/Ritonavir and Nirmatrelvir/Ritonavir in the Treatment of Moderate to Severe COVID‐19

Immunity, Inflammation and Disease, Volume 13, Issue 4, April 2025.
This is the first study comparing the effectiveness of simnotrelvir/ritonavir and nirmatrelvir/ritonavir in treating moderate and severe COVID‐19 patients. Patients who received simnotrelvir/ritonavir exhibited shorter hospitalization. Disease progression, viral clearance times, and symptom resolution time were similar between the two groups.
Xin Chen, Xiao‐Qing Lin, Fang Cheng, Shi‐Lin Zheng, Qiang Zhang, Te Wu, Xian‐Gao Jiang, Ji‐Chan Shi   +7 more
wiley   +1 more source

Cover Picture: Antiviral effectiveness and safety of azvudine in hospitalized SARS‐CoV‐2 patients with pre‐existing chronic respiratory diseases: A multicenter, retrospective cohort study (View 2/2025)

VIEW, Volume 6, Issue 2, April 2025.
In the cohort of SARS‐CoV‐2 infected patients with pre‐existing chronic respiratory diseases, azvudine can not only relieve disease symptoms by blocking the activity of the viral RNA polymeraseand inhibiting viral replication, but also perform immune‐enhancing effect by increasing the number and function of serum lymphocytes, and thus activating the ...
Junyi Sun, Mengzhao Yang, Daoke Yao, Yongjian Zhou, Xiaobo Hu, Guowu Qian, Yiqiang Yuan, Silin Li, Hong Luo, Shixi Zhang, Guangming Li, Donghua Zhang, Guotao Li, Yanyang Zhang, Xinjun Hu, Zujiang Yu, Guangying Cui, Zhigang Ren   +17 more
wiley   +1 more source

Clinical characteristics, diagnosis and short‐term outcomes of COVID‐19–associated acute myocarditis in China

ESC Heart Failure, Volume 12, Issue 1, Page 338-352, February 2025.
Abstract Aims Acute myocarditis (AM) has been recognized as a rare complication of coronavirus disease 2019 (COVID‐19) infection. This study was conducted to present the clinical characteristics, disease courses and short‐term prognoses of Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) induced AM in China, which has ...
Huihui Liu, Ping Zhou, Yan Huang, Sulan Yan, Lei Zhou, Chuanyu Gao, Lian Wang, Jianjun Tang, Qiong Zhou, Xinqing Li, Xiaofeng Zhuang, Mei Zhai, Liyan Huang, Xuemei Zhao, Barry Greenberg, David H. Hsi, Yuhui Zhang, Jian Zhang   +17 more
wiley   +1 more source

A Retrospective Analysis of Azvudine in Patients with COVID-19 and Pre-existing Cancer

Journal of Cancer
Objectives: Azvudine has been recommended as a potential treatment for the recently discovered Coronavirus disease (COVID-19) in 2019. However, the effectiveness of Azvudine in individuals who have both COVID-19 and pre-existing cancer remains uncertain.
Li, Fangyu, Zheng, Keao, Qi, Xueyan, Cui, Kaixia, Yang, Jing, Hao, Zhiying   +5 more
openaire   +2 more sources